溴结构域和额外末端结构域蛋白（BETs）在雌激素受体（ER）阳性乳腺癌中辅助Tam-R。
BETs abet Tam-R in ER-positive breast cancer.
作者信息
Alluri Prasanna G, Asangani Irfan A, Chinnaiyan Arul M
机构信息
1] Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
1] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
出版信息
Cell Res. 2014 Aug;24(8):899-900. doi: 10.1038/cr.2014.90. Epub 2014 Jul 8.
Abstract
Epigenetic modifications such as histone acetylation play a central role in the transcriptional regulation of many oncogenic drivers. Accumulating evidence suggests that pharmacological modulation of certain key epigenetic reader proteins such as BRD2/3/4 may serve as an attractive strategy for treatment of many cancers, including tamoxifen-resistant breast cancer.
摘要
表观遗传修饰，如组蛋白乙酰化，在许多致癌驱动因子的转录调控中起着核心作用。越来越多的证据表明，对某些关键表观遗传读取蛋白（如BRD2/3/4）进行药理学调节，可能是治疗包括抗他莫昔芬乳腺癌在内的多种癌症的一种有吸引力的策略。
相似文献
1
BETs abet Tam-R in ER-positive breast cancer.溴结构域和额外末端结构域蛋白（BETs）在雌激素受体（ER）阳性乳腺癌中辅助Tam-R。
Cell Res. 2014 Aug;24(8):899-900. doi: 10.1038/cr.2014.90. Epub 2014 Jul 8.
2
An epigenomic approach to therapy for tamoxifen-resistant breast cancer.一种针对他莫昔芬耐药性乳腺癌的表观基因组治疗方法。
Cell Res. 2014 Jul;24(7):809-19. doi: 10.1038/cr.2014.71. Epub 2014 May 30.
3
Disrupting the reader of histone language.扰乱组蛋白语言的解读者。
Angew Chem Int Ed Engl. 2011 Jun 20;50(26):5801-3. doi: 10.1002/anie.201101414. Epub 2011 May 25.
4
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.癌症类型特异性SPOP突变体对BET蛋白降解及对BET抑制剂敏感性的相反作用。
Nat Med. 2017 Sep;23(9):1046-1054. doi: 10.1038/nm.4372. Epub 2017 Aug 14.
5
Targeting the BET family for the treatment of leukemia.靶向BET家族用于白血病治疗。
Epigenomics. 2014 Apr;6(2):153-5. doi: 10.2217/epi.14.5.
6
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.SPOP 突变型前列腺癌中内在的 BET 抑制剂耐药性由 BET 蛋白稳定化和 AKT-mTORC1 激活介导。
Nat Med. 2017 Sep;23(9):1055-1062. doi: 10.1038/nm.4379. Epub 2017 Aug 14.
7
Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.雌激素受体阳性（ER+）乳腺癌中，MYC的表观遗传调控驱动对依维莫司的耐药性。
Oncotarget. 2015 Feb 10;6(4):2407-20. doi: 10.18632/oncotarget.2964.
8
Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.药物靶向 BET 溴结构域后相互作用组的重排。
Mol Cell. 2019 Feb 7;73(3):621-638.e17. doi: 10.1016/j.molcel.2018.11.006. Epub 2018 Dec 13.
9
10
pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer.pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300和pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1多分子复合物介导乳腺癌中雌激素受体α的转录。
Oncogene. 2003 Jun 5;22(23):3511-7. doi: 10.1038/sj.onc.1206578.
引用本文的文献
1
Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both and .靶向BRD4末端外结构域的肽抑制剂可有效抑制乳腺癌的生长和转移。
J Med Chem. 2024 Apr 25;67(8):6658-6672. doi: 10.1021/acs.jmedchem.4c00141. Epub 2024 Apr 3.
2
BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer.抑制BRD4作为延长雌激素受体阳性乳腺癌对标准治疗反应的一种策略。
Cancers (Basel). 2023 Aug 11;15(16):4066. doi: 10.3390/cancers15164066.
3
HBXIP blocks myosin-IIA assembly by phosphorylating and interacting with NMHC-IIA in breast cancer metastasis.在乳腺癌转移过程中，HBXIP通过磷酸化并与非肌肉肌球蛋白重链-IIA（NMHC-IIA）相互作用来阻断肌球蛋白-IIA的组装。
Acta Pharm Sin B. 2023 Mar;13(3):1053-1070. doi: 10.1016/j.apsb.2022.11.025. Epub 2022 Nov 25.
4
The emerging role of BET inhibitors in breast cancer.BET 抑制剂在乳腺癌中的新兴作用。
Breast. 2020 Oct;53:152-163. doi: 10.1016/j.breast.2020.08.005. Epub 2020 Aug 13.
5
Acetylation of histone H3K27 signals the transcriptional elongation for estrogen receptor alpha.组蛋白 H3K27 的乙酰化信号表明雌激素受体 α 的转录延伸。
Commun Biol. 2020 Apr 7;3(1):165. doi: 10.1038/s42003-020-0898-0.
6
Epigenetic therapies in heart failure.心力衰竭的表观遗传学治疗。
J Mol Cell Cardiol. 2019 May;130:197-204. doi: 10.1016/j.yjmcc.2019.04.012. Epub 2019 Apr 13.
7
TRPS1 regulates oestrogen receptor binding and histone acetylation at enhancers.TRPS1 调节雌激素受体结合和增强子处的组蛋白乙酰化。
Oncogene. 2018 Sep;37(39):5281-5291. doi: 10.1038/s41388-018-0312-2. Epub 2018 Jun 12.
8
The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.BET 抑制剂 I-BET762 抑制胰腺导管腺癌细胞增殖并增强吉西他滨的治疗效果。
Sci Rep. 2018 May 25;8(1):8102. doi: 10.1038/s41598-018-26496-0.
9
BEclear: Batch Effect Detection and Adjustment in DNA Methylation Data.BEclear：DNA甲基化数据中的批次效应检测与调整
PLoS One. 2016 Aug 25;11(8):e0159921. doi: 10.1371/journal.pone.0159921. eCollection 2016.
10
The changing role of ER in endocrine resistance.内质网在内分泌抵抗中不断变化的作用。
Breast. 2015 Nov;24 Suppl 2(0 2):S60-6. doi: 10.1016/j.breast.2015.07.015. Epub 2015 Aug 10.
本文引用的文献
1
An epigenomic approach to therapy for tamoxifen-resistant breast cancer.一种针对他莫昔芬耐药性乳腺癌的表观基因组治疗方法。
Cell Res. 2014 Jul;24(7):809-19. doi: 10.1038/cr.2014.71. Epub 2014 May 30.
2
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.在去势抵抗性前列腺癌中靶向治疗 BET 溴结构域蛋白。
Nature. 2014 Jun 12;510(7504):278-82. doi: 10.1038/nature13229. Epub 2014 Apr 23.
3
Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer.破坏 BRD4 与乙酰化 Twist 的相互作用可抑制基底样乳腺癌的肿瘤发生。
Cancer Cell. 2014 Feb 10;25(2):210-25. doi: 10.1016/j.ccr.2014.01.028.
4
A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.雄激素受体轴靶向治疗去势抵抗性前列腺癌的路线图
Cancer Res. 2013 Aug 1;73(15):4599-605. doi: 10.1158/0008-5472.CAN-12-4414. Epub 2013 Jul 25.
5
Selective inhibition of tumor oncogenes by disruption of super-enhancers.通过破坏超级增强子选择性抑制肿瘤癌基因。
Cell. 2013 Apr 11;153(2):320-34. doi: 10.1016/j.cell.2013.03.036.
6
Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.乳腺癌内分泌耐药：分子途径与靶向治疗的合理开发。
Future Oncol. 2012 Mar;8(3):273-92. doi: 10.2217/fon.12.8.
7
Pathogenesis of NUT midline carcinoma.NUT 中线癌的发病机制。
Annu Rev Pathol. 2012;7:247-65. doi: 10.1146/annurev-pathol-011811-132438. Epub 2011 Oct 17.
8
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.抑制 BET 募集到染色质可作为治疗 MLL 融合白血病的有效方法。
Nature. 2011 Oct 2;478(7370):529-33. doi: 10.1038/nature10509.
9
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.鉴定人类三阴性乳腺癌亚型和临床前模型以选择靶向治疗药物。
J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014.
10
Selective inhibition of BET bromodomains.选择性抑制 BET 溴结构域。
Nature. 2010 Dec 23;468(7327):1067-73. doi: 10.1038/nature09504. Epub 2010 Sep 24.
Zotero 插件